Merriman Curhan Positive On Celldex Therapeutics (CLDX) After Results and Ahead of Events
More News related to CLDX
- Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009
- Merriman Curhan Positive On Celldex Therapeutics (CLDX) After Results and Ahead of Events
- Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results
- Celldex Therapeutics (CLDX) Announces Positive Results From Phase Studies of CDX-1307
- Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307
Merriman Curhan Ford issues comments on Celldex Therapeutics, Inc. (Nasdaq: CLDX) after Q3 results. The firm expect positive incremental catalysts in the near term. "Updated Phase II breast cancer data with CDX-011 (formerly Curagen's CRO-011) will be presented at the San Antonio Breast Cancer Symposium, December 9-13." The firm reiterated their Buy rating and $14-$15 price target.
Related Categories
Analyst CommentsFDA
Stocks Mentioned
-0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
